We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Microfluidic Motility Device Indicates Likelihood of Breast Tumor Metastasis

By LabMedica International staff writers
Posted on 10 Jun 2019
Print article
Image: Examples of migratory and non-migratory MDA-MB-231 breast cancer cells migrating in the MAqCI (Microfluidic Assay for quantification of Cell Invasion) device (Photo courtesy of Christopher L. Yankaskas, Johns Hopkins University).
Image: Examples of migratory and non-migratory MDA-MB-231 breast cancer cells migrating in the MAqCI (Microfluidic Assay for quantification of Cell Invasion) device (Photo courtesy of Christopher L. Yankaskas, Johns Hopkins University).
A novel microfluidic motility test was shown to accurately predict a breast tumor's likelihood to generate metastases.

The difficulties involved in predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. To meet this predictive challenge, investigators at Johns Hopkins University (Baltimore, MD, USA) development a microfluidic assay that quantified the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential anti-metastatic therapeutics.

The device comprised Y-shaped microchannels with dimensions chosen to mimic aspects of the complexity and variety of the cross-sectional areas of tissue tracks found in or along different locations in the body. This Microfluidic Assay for quantification of Cell Invasion (MAqCI) was designed to evaluate three key features of metastasis: cancer cells’ ability to move, their ability to compress in order to enter narrow channels, and their ability to proliferate.

The MAqCI device, which is now patented in the United States, was used in conjunction with a computerized inverted microscope having phase contrast and fluorescence imaging capabilities. Cell migration was monitored in real time via time-lapse phase contrast microscopy. Results of experiments conducted with the MAqCI device revealed that compared to an unsorted population of cancer cells, highly motile cells isolated by the device exhibited similar tumorigenic potential but markedly increased metastatic propensity in vivo.

RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes.

“When a lump is detected in a patient’s body, the doctor can determine if the mass is benign or malignant through a biopsy, but they cannot really say with confidence if a malignant tumor is going to be highly aggressive and metastasize to other locations,” said senior author Dr. Konstantinos Konstantopoulos, professor of biomedical engineering and oncology at Johns Hopkins University. “Although liquid biopsies or circulating tumor DNA measurements can be very good at monitoring a patient’s response to therapy after it is administered, they do not provide a means to help physicians select optimal drugs to prevent spread.”

Use of the MAqCI device was described in the May 6, 2019, online edition of the journal Nature Biomedical Engineering.

Related Links:
Johns Hopkins University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.